Does Injection Number Matter? A Systematic Review and Meta-Analysis of Bladder Botox for Overactive Bladder

Read full text Summarise with VIRAT
Authors: B. Roberts, Pal Sudhirkumar Shah, Caitlin E. Carlton, Karissa A. Leong, Brittany Suarez, Dara C Kissel, S. Kehoe, Elena Uttaro, Katherine Tepper, Elizabeth D. Drugge, Bradley E. Jacobs, R. Rogers
+1 more Cara L. Grimes
Cited by: 0
References: 25

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Introduction and Hypothesis Intravesical onabotulinumtoxin-A (BoNT-A) is an established treatment for overactive bladder (OAB). Although the FDA-approved standard regimen involves 20-injections, evidence suggests fewer injections may achieve comparable outcomes. Objectives To systematically review studies comparing periprocedural outcomes of reduced-injection versus standard 20-injection BoNT-A techniques for OAB. Study Design PubMed, Scopus, and Embase were searched from their inception through 6/11/2026. Eligible studies included women undergoing in-office bladder BoNT-A (100 U) for OAB. The intervention was a reduced number of injections and the comparator was the 20-injection protocol. Outcomes included efficacy, pain during injection, urinary tract infections (UTI), and retention. Abstracts and full-text articles were doubly screened; accepted articles were doubly extracted. Study quality was assessed using GRADE criteria, ROB2, and ROBIN-I. Random-effects meta-analyses were performed to pool proportions and risk ratios. Results We screened 4066 abstracts, 139 full-text papers were assessed, leaving 16 studies (eight RCTs and three retrospective cohort studies, four prospective cohort study, and one case series) with 1393 patients. Most outcomes were supported by low- to high-quality evidence. Mean follow-up was 8.7 ± 4.3 weeks, and the reduced-injection groups received a mean of 7.3 ± 2.8 injection sites. Meta-analysis demonstrated no difference in efficacy between reduced- and standard-injection protocols (79% (95% CI 0.66–0.89); p = 0.16). Pain scores were not different between the reduced-injection group and the standard-injection group (mean difference 0 (95% CI 0.36–0.34); p = 0.23)). UTI (16% (95% CI 0.12–0.21); p = 0.427) and urinary retention (4% (95% CI 0.02–0.06); p = 0.591) adverse events did not vary between groups. Conclusions Reduced-injection BoNT-A regimens provide efficacy and safety comparable to the 20-injection protocol, supporting a simplified approach to OAB treatment without compromising outcomes.

Fields of Study & Subjects

Urinary Bladder and Prostate Research Pelvic floor disorders treatments Urinary Tract Infections Management

Publication details

Journal / source
International Urogynecology Journal
Volume
147
Issue
4S
Pages
13S–14S
Publication date
20 March 2026
Language
EN